18 research outputs found
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed.[Results]: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events.[Conclusion]: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents
The Comparison of Filgrastim and Lenograstim on Hematologic Effects after Chemotherapy in Children with Acute Lymphoblastic Leukemia
INSURE: A pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice - supplementary material
Supplementary methods, tables and figures </p
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
Multiple available combinations of proteasome inhibitors,
immunomodulators (IMIDs), and monoclonal antibodies are shifting the
relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of
head-to-head trials of triplet regimens highlights the need for
real-world (RW) evidence. We conducted an RW comparative effectiveness
analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and
daratumumab (D) combined with either lenalidomide or pomalidomide plus
dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients
initiating triplet regimens in line of therapy (LOT) >= 2 on/after
1/1/2014 was followed between 1/2007 and 3/2018 in Optum’s deidentified
US electronic health records database. Time to next treatment (TTNT) was
estimated using Kaplan-Meier methods; regimens were compared using
covariate-adjusted Cox proportional hazard models. Seven hundred
forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349;
KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient
LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd,
n = 45) in LOTs >= 2 were identified. More patients >= 75 years received
IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More
patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted
median TTNT in LOT >= 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not
estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In
covariate-adjusted analysis, only KRd vs DRd was associated with a
significantly higher risk of next LOT initiation/death (HR 1.72; P =
0.0142); no Pd triplet was significantly different vs DPd in LOT >= 2.
Our data highlight important efficacy/effectiveness gaps between results
observed in phase 3 clinical trials and those realized in the RW